Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Nations stockpile mpox vaccine amid rising geopolitical fears
9 Jul 2025, 14:48BAVA.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline13 Dec 2019
Bavarian Nordic A/S - Articles of Association29 Nov 2019
Bavarian Nordic A/S – Report on the Results of the Extraordinary General Meeting, held November 27, 201927 Nov 2019
Bavarian Nordic Announces Appointment of Jean-Christophe May as Executive Vice President and Chief Commercial Officer13 Nov 2019
Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen7 Nov 2019
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such7 Nov 2019
Bavarian Nordic Announces Interim Results for the First Nine Months of 2019
Search

Danish vaccine maker Bavarian Nordic will supply an undisclosed European country with its smallpox and mpox vaccine under a new contract valued at over 200 million Danish Krone, the company announced Wednesday.

Bavarian Nordic sells vaccine voucher for $160 million
20 Jun 2025, 17:26BAVA.CONASDAQ Copenhagen

Danish vaccine company Bavarian Nordic has entered an agreement to sell a Priority Review Voucher for a total of $160 million, the company said Wednesday.

  • Previous
  • 1
  • 2
  • 3
  • Next
7 Nov 2019
Bavarian Nordic A/S – Notice Convening Extraordinary General Meeting 25 Oct 2019
Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline21 Oct 2019
Bavarian Nordic Updates on Phase 2 Study of CV301 in Bladder Cancer 18 Oct 2019
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine 8 Oct 2019
Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults24 Sept 2019
  • Previous
  • 1
  • More pages
  • 24
  • 25
  • 26
  • More pages
  • 78
  • Next
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
Filings
927